# Camillo Porta

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/camillo-porta/

## Facts

| Field | Value |
| --- | --- |
| Citations | 58,290 |
| Field | Renal cell carcinoma treatment |
| h-index | 80 |
| i10-index | 434 |
| Last Known Institution | Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari |
| OpenAlex ID | https://openalex.org/A5018910230 |
| ORCID iD | https://orcid.org/0000-0003-2412-1563 |
| Works | 987 |

## Researcher papers

- [Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-ipilimumab-versus-sunitinib-in-advanced-renal-cell-carcinoma/)
- [Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-or-everolimus-for-advanced-renal-cell-carcinoma/)
- [Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma](https://scholariq.org/papers/nivolumab-plus-cabozantinib-versus-sunitinib-for-advanced-renal-cell-carcinoma/)
- [Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial](https://scholariq.org/papers/safety-and-efficacy-of-sunitinib-for-metastatic-renal-cell-carcinoma-an-expanded/)
- [Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/renal-cell-carcinoma-esmo-clinical-practice-guideline-for-diagnosis-treatment/)
- [Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival](https://scholariq.org/papers/evaluation-of-clear-cell-papillary-and-chromophobe-renal-cell-carcinoma/)
- [Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-in-first-line-treatment-of/)
- [Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-versus-sunitinib-as-first-line-treatment-of/)

## Researcher topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Renal and related cancers](https://scholariq.org/topics/renal-and-related-cancers/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)

## Researcher university

- [Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari](https://scholariq.org/institutions/azienda-universitaria-ospedaliera-consorziale-policlinico-bari/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.